Synapse - Breast Medicine Service

Results (4181)

Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers

Meeting Abstract

Jhaveri, K.; Han, H.; Dotan, E.; Oh, D. Y.; Ferrario, C.; Tolcher, A.; Lee, K. W.; Liao, C. Y.; Kang, Y. K.; Kim, Y. H.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

ACE-Breast-03: A phase II study patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens treated with ARX788

Meeting Abstract

Hurvitz, S. A.; Kalinsky, K.; Tripathy, D.; Sledge, G.; Gradishar, W. J.; O'Shaughnessy, J.; Modi, S.; Park, H.; McCartney, A.; Frentzas, S.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)

Meeting Abstract

Ueno, N. T.; Jacot, W.; Yamashita, T.; Sohn, J.; Tokunaga, E.; Prat, A.; Tsurutani, J.; Park, Y. H.; Rugo, H. S.; Xu, B.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study

Meeting Abstract

Schmid, P.; Cortés, J.; Marmé, F.; Rugo, H. S.; Tolaney, S. M.; Oliveira, M.; Loirat, D.; Jhaveri, K.; Yoon, O. K.; Motwani, M.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

An AI-driven computational biomarker from H&E slides recovers cases with low levels of HER2 from immunohistochemically HER2-negative breast cancers

Meeting Abstract

Marra, A.; Goldfinger, M.; Millar, E.; Hanna, M.; Rothrock, B.; Lee, M.; Wang, Y.; van Eck, A.; Tydlitatova, L. T.; Sue, J.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET) +/- CDK 4/6 inhibition (CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC)

Meeting Abstract

Marra, A.; Gazzo, A.; Gupta, A.; Selenica, P.; Da Silva, E. M.; Pareja, F.; Pei, X.; Zhu, Y.; Razavi, P.; Safonov, A.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Inherited germline cancer susceptibility gene variants in individuals with non-muscle-invasive bladder cancer

Journal Article

Pietzak, E. J.; Whiting, K.; Srinivasan, P.; Bandlamudi, C.; Khurram, A.; Joseph, V.; Walasek, A.; Bochner, E.; Clinton, T.; Almassi, N.; more...
Clinical Cancer Research (2022)

Fulltext@MSK | Save

Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: A phase II risk-adapted design

Journal Article

Kumar, A.; Casulo, C.; Joffe, E.; Moskowitz, C.; Gerecitano, J.; Moskowitz, A.; Younes, A.; Drullinsky, P.; Drill, E.; Choma, M.; more...
Leukemia and Lymphoma (2022)

Fulltext@MSK | Save

APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas

Journal Article

Selenica, P.; Marra, A.; Choudhury, N. J.; Gazzo, A.; Falcon, C. J.; Patel, J.; Pei, X.; Zhu, Y.; Ng, C. K. Y.; Curry, M.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Journal Article

Geyer, C. E. Jr; Garber, J. E.; Gelber, R. D.; Yothers, G.; Taboada, M.; Ross, L.; Rastogi, P.; Cui, K.; Arahmani, A.; Aktan, G.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save